Most Recent
Litigators of the week: Atanaskovic Hartnell, Marque win wars over words
A "time poor" judge's extensive copying and pasting of submissions and an offensive tweet by senator Pauline Hanson were at the centre of the week's biggest litigation wins.
Full Court puts Bed Bath N’ Table’s misleading conduct claims to sleep
In a loss for Bed Bath N' Table, the Full Court has overturned a finding that homewares retailer House engaged in misleading and deceptive conduct by setting up its 'Bed & Bath' stores.
Cipla attacks patent extension for Novo Nordisk weight loss drug
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
Government wants to stay 12-year-old dispute over Abilify generic
The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.
AstraZeneca sues to put the brakes on Brilinta generic
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta. 
Element Zero appeals search order win for Fortescue in trade secrets case
Green iron start-up Element Zero is continuing its fight over search orders won by rival Fortescue that it claimed were a massive over-reach.
IP case over basmati rice to venture into ‘darker corners’ of trade mark law
The scope of protection for geographical indications will be at issue in India's appeal of a decision that barred it from registering a trade mark for basmati rice.
Coles dodges iFit challenge to Perform powerbar brand
Coles has defeated a trade mark challenge to its Perform brand of sports nutrition products by a sports equipment company.
Bayer’s patents for blockbuster blood thinner Xarelto invalid: court
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.